✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Glycopyrrolate is a drug marketed by Abraxis Pharm, Accord Hlthcare, Am Regent, Amneal, Apotex, Athenex Inc, Caplin, Eugia Pharma, Fresenius Kabi Usa, Gland Pharma Ltd, Hikma Farmaceutica, Hospira, Meitheal, Nivagen Pharms Inc, Piramal Critical, Prinston Inc, Sandoz Inc, Somerset Theraps Llc, Teva Parenteral, Watson Labs, Xiromed, Zydus Pharms, Annora Pharma, Par Pharm Inc, Suven Pharms, Alembic Labs, Aurolife Pharma Llc, Chartwell Rx, Dr Reddys Labs Ltd, Heritage Pharms Inc, Hikma Intl Pharms, Kenton, Leading Pharma Llc, Lgm Pharma, Natco, Oxford Pharms, Par Pharm, Rising, and Sun Pharm Inds Ltd. and is included in forty-six NDAs.
The generic ingredient in GLYCOPYRROLATE is glycopyrrolate. There are seventeen drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the glycopyrrolate profile page.
A generic version of GLYCOPYRROLATE was approved as glycopyrrolate by AM REGENT on July 23rd, 1986.
Summary for GLYCOPYRROLATE
|Finished Product Suppliers / Packagers:||39|
|Raw Ingredient (Bulk) Api Vendors:||102|
|Formulation / Manufacturing:||see details|
|Drug Prices:||Drug price information for GLYCOPYRROLATE|
|Patent Litigation and PTAB cases:||See patent lawsuits and PTAB cases for GLYCOPYRROLATE|
|What excipients (inactive ingredients) are in GLYCOPYRROLATE?||GLYCOPYRROLATE excipients list|
|DailyMed Link:||GLYCOPYRROLATE at DailyMed|
Recent Clinical Trials for GLYCOPYRROLATE
Identify potential brand extensions & 505(b)(2) entrants
|Emory University||Phase 4|
|Kangbuk Samsung Hospital||N/A|